Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 507

Similar articles for PubMed (Select 23400082)

1.

Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.

Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.

Retina. 2013 Mar;33(3):467-73. doi: 10.1097/IAE.0b013e3182753b2a.

PMID:
23400082
2.

Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.

Ozkaya A, Alkin Z, Yazici AT, Demirok A.

Retina. 2014 May;34(5):853-9. doi: 10.1097/IAE.0000000000000024.

PMID:
24141904
3.

Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.

Saito M, Iida T, Kano M.

Retina. 2012 Jul;32(7):1250-9. doi: 10.1097/IAE.0b013e318236e503.

PMID:
22446886
4.

Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.

Weinberg DV, Shapiro H, Ehrlich JS.

Ophthalmology. 2013 Jun;120(6):1278-82. doi: 10.1016/j.ophtha.2012.11.042. Epub 2013 Feb 28.

PMID:
23453513
5.

Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.

Rush RB, Simunovic MP, Vandiver L, Aragon AV 2nd, Ysasaga JE.

Retina. 2014 May;34(5):846-52. doi: 10.1097/IAE.0000000000000033.

PMID:
24240560
6.

Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.

Cho HJ, Koh KM, Kim JH, Kim HS, Han JI, Lew YJ, Lee TG, Kim JW.

Retina. 2015 Feb;35(2):205-12. doi: 10.1097/IAE.0000000000000295.

PMID:
25105310
7.

Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.

Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.

Am J Ophthalmol. 2014 May;157(5):1013-21. doi: 10.1016/j.ajo.2014.01.019. Epub 2014 Jan 30.

PMID:
24487050
8.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022. Epub 2012 May 1.

PMID:
22551738
9.

Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.

Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.

Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.

PMID:
22414958
10.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

11.

Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.

Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB.

Retina. 2013 Sep;33(8):1605-12. doi: 10.1097/IAE.0b013e31828e8551.

PMID:
23549101
12.

Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.

Cho HJ, Kim CG, Yoo SJ, Cho SW, Lee DW, Kim JW, Lee JH.

Am J Ophthalmol. 2013 Jan;155(1):118-126.e1. doi: 10.1016/j.ajo.2012.07.009. Epub 2012 Sep 27.

PMID:
23022163
13.

Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.

Mimoun G, Caillaux V, Querques G, Rothschild PR, Puche N, Souied EH.

Retina. 2013 Mar;33(3):513-21. doi: 10.1097/IAE.0b013e3182753adb.

PMID:
23400081
14.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
15.

Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.

Lim JY, Lee SY, Kim JG, Lee JY, Chung H, Yoon YH.

Acta Ophthalmol. 2012 Feb;90(1):61-7. doi: 10.1111/j.1755-3768.2009.01841.x. Epub 2010 Mar 16.

16.

Association between foveal microstructure and visual outcome in age-related macular degeneration.

Shin HJ, Chung H, Kim HC.

Retina. 2011 Sep;31(8):1627-36. doi: 10.1097/IAE.0b013e31820d3d01.

PMID:
21606888
17.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
18.

Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.

Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.

Retina. 2014 May;34(5):860-7. doi: 10.1097/IAE.0000000000000007.

PMID:
24756034
19.

Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.

Krebs I, Vécsei Marlovits V, Bodenstorfer J, Glittenberg C, Ansari Shahrezaei S, Ristl R, Binder S.

Acta Ophthalmol. 2013 May;91(3):e178-83. doi: 10.1111/aos.12018. Epub 2012 Dec 14.

20.

Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.

Cho HJ, Baek JS, Lee DW, Cho SW, Kim CG, Kim JW.

Retina. 2013 Nov-Dec;33(10):2126-32. doi: 10.1097/IAE.0b013e3182899296.

PMID:
23609123
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk